Trial Profile

Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Momelotinib (Primary)
Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
Focus Adverse reactions; Therapeutic Use
Sponsors Gilead Sciences; GSK

Most Recent Events

20 Apr 2026 Planned End Date changed from 31 Dec 2026 to 11 Dec 2026.
20 Apr 2026 Planned primary completion date changed from 31 Dec 2026 to 11 Dec 2026.
16 Jun 2023 Planned End Date changed from 1 Dec 2026 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com